全文获取类型
收费全文 | 702篇 |
免费 | 52篇 |
国内免费 | 22篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 49篇 |
妇产科学 | 6篇 |
基础医学 | 69篇 |
口腔科学 | 42篇 |
临床医学 | 61篇 |
内科学 | 121篇 |
皮肤病学 | 32篇 |
神经病学 | 15篇 |
特种医学 | 218篇 |
外科学 | 27篇 |
综合类 | 34篇 |
预防医学 | 35篇 |
眼科学 | 4篇 |
药学 | 21篇 |
肿瘤学 | 41篇 |
出版年
2019年 | 3篇 |
2018年 | 5篇 |
2017年 | 5篇 |
2016年 | 8篇 |
2015年 | 7篇 |
2014年 | 13篇 |
2013年 | 8篇 |
2012年 | 4篇 |
2011年 | 6篇 |
2010年 | 18篇 |
2009年 | 20篇 |
2008年 | 19篇 |
2007年 | 11篇 |
2006年 | 13篇 |
2005年 | 7篇 |
2004年 | 10篇 |
2003年 | 8篇 |
2002年 | 3篇 |
2001年 | 14篇 |
2000年 | 8篇 |
1999年 | 12篇 |
1998年 | 39篇 |
1997年 | 44篇 |
1996年 | 40篇 |
1995年 | 35篇 |
1994年 | 23篇 |
1993年 | 31篇 |
1992年 | 19篇 |
1991年 | 17篇 |
1990年 | 13篇 |
1989年 | 23篇 |
1988年 | 28篇 |
1987年 | 44篇 |
1986年 | 25篇 |
1985年 | 16篇 |
1984年 | 8篇 |
1983年 | 12篇 |
1982年 | 14篇 |
1981年 | 20篇 |
1980年 | 17篇 |
1979年 | 8篇 |
1978年 | 6篇 |
1977年 | 9篇 |
1976年 | 21篇 |
1975年 | 10篇 |
1934年 | 4篇 |
1933年 | 3篇 |
1930年 | 3篇 |
1927年 | 4篇 |
1926年 | 4篇 |
排序方式: 共有776条查询结果,搜索用时 15 毫秒
71.
Gene Probe Analysis in an Informative Family with Multiple Endocrine Neoplasia Syndrome Type 2A (MEN 2A). Improvement in Carrier Risk Estimation 总被引:2,自引:0,他引:2
MORRISON PJ; HADDEN DR; HUGHES AE; KENNEDY L; RUSSELL CJF; NEVIN NC 《QJM : monthly journal of the Association of Physicians》1991,80(1):597-603
Gene probe analysis of the MEN 2A locus on chromosome 10 hasbeen undertaken using the markers TB10.163, RBP 3 and TB14.34in a large kindred with familial medullary thyroid carcinomas,with or without phaeochromocytomas or primary hyperparathyroidism.A maximum LOD score of 2.97 gave strong evidence of close linkagewith zero recombination. For 12 members of the family so far not known to be affectedby any form of the disease the estimated risk of carrying thegene has been considerably decreased in all but one, whose riskhas been greatly increased. 相似文献
72.
DR Hadden 《The Ulster medical journal》1992,61(1):124-125
73.
74.
75.
RICHARD D. GENTZLER ERIC H. LUCAS NORTH AMERICAN TRILOGY DR+ PHASE I CLINICAL INVESTIGATORS 《Pacing and clinical electrophysiology : PACE》1996,19(11):1809-1812
A new feature (AutoSlope) has been introduced that can automatically adjust the sensor slope based on the chronic activity level of the patient. The algorithm adjusts the slope once per week so that 99% of the sensor response is maintained between the base rate and 23% of the difference between the programmed Base Rate and the Max Sensor Rate. Offsets are available for fine titration of sensor response in individual patients. The AutoSlope feature was evaluated in 93 patients with DDDR pacemakers (Trilogy DR+, Pacesetter). Patients were seen at 1, 3, and 6 months for a total of 178 evaluations. At each evaluation, the AutoSlope value was recorded. Patients then performed a brisk walk at sensor values equivalent to the AutoSlope value. Desired sensor rate was compared to the rate achieved by AutoSlope for the exercise period. Long-term sensor performance was evaluated by analyzing the sensor histogram. AutoSlope provided the desired sensor rate in most patients. Use of AutoSlope offsets allows fine titration of rate modulation in individual patients. Ongoing changes in sensor performance provided by AutoSlope allow patients to achieve a desired sensor rate from one evaluation to another without changes in permanent programmed settings. Programming a low maximum sensor rate may limit sensor response in some patients. 相似文献
76.
We have found that the addition of 10 mM inorganic phosphate to DHA in CPD-adenine maintains ATP levels at normal or higher than normal values for six weeks of storage. 2,3-DPG values are slightly lowered by the extra phosphate, but are still maintained at approximately half normal for four weeks by the DHA. The addition of a higher phosphate concentration, 20 mM, to DHA produced lower levels of ATP and 2,3-DPG than those observed with 10 mM phosphate, although both levels were better than in the CPD-adenine control. pH values in this experiment were lowest in the three preservatives containing DHA, probably indicating increased lactate production due to metabolism of this triose sugar, in addition to dextrose present in CPD. 相似文献
77.
Expression and structure of CD22 in acute leukemia 总被引:1,自引:0,他引:1
The purpose of this study was to examine the expression and structure of CD22 in B cell precursor acute lymphoblastic leukemia (BCP-ALL), acute myeloid leukemia (AML), and T cell acute lymphoblastic leukemia (T-ALL). By using immunofluorescence microscopy and flow cytometry we observed that CD22 is expressed not only in the cytoplasm (as previously reported) but also on the cell surface of virtually all (15/16) BCP-ALL examined. CD22 that was biosynthetically labeled with 35S-cysteine and immunoprecipitated from the uncommon cytoplasmic CD22- positive/surface CD22-negative BCP-ALL cells was analyzed by single- dimension sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Our results indicated that the cytoplasmic form of CD22 comigrated with 125I/lactoperoxidase-labeled surface CD22. Therefore, cytoplasmic CD22 is probably a pool of fully processed glycoprotein. We also observed unusual cases of AML (approximately 20%) that expressed cytoplasmic CD22 based on immunofluorescent staining; however, biosynthetic labeling and immunoprecipitation revealed an apparently cross-reactive protein(s) of approximately 250 to 300 kd in AML cells. No T-ALL cell lines examined expressed either cytoplasmic or surface CD22. Thus, cytoplasmic and surface expression of bona fide CD22 appears restricted to B cells, which suggests that this molecule subserves a function unique to B cells. 相似文献
78.
Stephens RW; Golder JP; Fayle DR; Hume DA; Hapel AJ; Allan W; Fordham CJ; Doe WF 《Blood》1985,66(2):333-337
Adherent monolayer cultures of human blood monocytes, peritoneal macrophages, bone marrow macrophages, and colonic mucosa macrophages were examined for their ability to produce and secrete minactivin, a specific inactivator of urokinase-type plasminogen activator. All except colonic mucosa macrophages produced and secreted appreciable amounts of minactivin, but only blood monocytes were stimulated by muramyl dipeptide (adjuvant peptide) to increase production. The minactivin from each of these populations could be shown to preferentially inhibit urokinase-type plasminogen activator and not trypsin, plasmin, or "tissue"-type plasminogen activator (HPA66). A plasminogen-activating enzyme present in monocyte cultures appeared unaffected by the presence of minactivin and could be shown to be regulated independently by dexamethasone. 相似文献
79.
This study described the binding of platelet plasma membranes to either control or thrombin-activated platelets. Glycoproteins in plasma membranes isolated from human platelets were labeled by oxidation with periodate followed by reduction with [3H]NaBH4. Labeled membranes were incubated with either control or thrombin-activated platelets. The amount of membranes bound was measured by separating platelets with bound membranes from solution by rapid centrifugation through 27% sucrose and determining the amount of radioactivity associated with platelets. Five- to sevenfold more membranes bound to thrombin- activated platelets than to control platelets. This enhanced binding of labeled membranes was completely inhibited by an excess of unlabeled platelet membranes. Human erythrocyte membranes had little affinity for either washed or thrombin-activated platelets and therefore did not compete for platelet-membrane binding. Binding of platelet membranes to thrombin-treated platelets was inhibited by prior incubation of the platelets with PGI2 suggesting that the enhanced binding of membranes was to activated platelets. This study demonstrates that the purified platelet membranes have functional sites that can mediate membrane binding to platelets and that quantitation of membrane binding appears to reflect the increased aggregation capability of activated platelets. 相似文献
80.
Matthews DC; Appelbaum FR; Eary JF; Fisher DR; Durack LD; Bush SA; Hui TE; Martin PJ; Mitchell D; Press OW 《Blood》1995,85(4):1122-1131
In an attempt to decrease the relapse rate after bone marrow transplantation (BMT) for advanced acute leukemia, we initiated studies using 131I-labeled anti-CD45 antibody (BC8) to deliver radiation specifically to hematopoietic tissues, followed by a standard transplant preparative regimen. Biodistribution studies were performed in 23 patients using 0.5 mg/kg trace 131I-labeled BC8 antibody. The BC8 antibody was cleared rapidly from plasma with an initial disappearance half-time of 1.5 +/- 0.2 hours, presumably reflecting rapid antigen- specific binding. The mean radiation absorbed doses (cGy/mCi131I administered) were as follows: marrow, 7.1 +/- 0.8; spleen, 10.8 +/- 1.4; liver, 2.7 +/- 0.2; lungs, 2.1 +/- 0.1; kidneys, 0.7 +/- 0.1; and total body, 0.4 +/- 0.03. Patients with acute myelogenous leukemia (AML) in relapse had a higher marrow dose (11.4 cGy/mCi) than those in remission (5.2 cGy/mCi; P = .001) because of higher uptake and longer retention of radionuclide in marrow. Twenty patients were treated with a dose of 131I estimated to deliver 3.5 Gy (level 1) to 7 Gy (level 3) to liver, with marrow doses of 4 to 30 Gy and spleen doses of 7 to 60 Gy, followed by 120 mg/kg cyclophosphamide (CY) and 12 Gy total body irradiation (TBI). Nine of 13 patients with AML or refractory anemia with excess blasts (RAEB) and two of seven with acute lymphocytic leukemia (ALL) are alive disease-free at 8 to 41 months (median, 17 months) after BMT. Toxicity has not been measurably greater than that of CY/TBI alone, and the maximum tolerated dose has not been reached. This study demonstrates that with the use of 131I-BC8 substantially greater doses of radiation can be delivered to hematopoietic tissues as compared with liver, lung, or kidney, which may improve the efficacy of marrow transplantation. 相似文献